Carlos Prada
Clinical Genetics (M.D.) · Chicago, ILNPI 1386851335
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 74.8% of it on its own, with 12 other manufacturers making up the rest.
Across 252 payments — averaging $1201.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$226K
- Biomarin Pharmaceutical Inc.$28K
- Amicus Therapeutics, Inc.$20K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Shire North American Group Inc$7K
- Chiesi USA, Inc.$7K
- plus $2K from 7 others
Across 103 payments — averaging $7361.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$334K
- Sanofi$261K
- Sanofi US Services Inc.$69K
- Modernatx, Inc.$65K
- Ultragenyx Pharmaceutical Inc.$15K
- Orchard Therapeutics North America$7K
- plus $7K from 2 others
What the payments were for
- Consulting fees$151,97550%
- Speaking & faculty fees$110,97737%
- Travel & lodging$31,82411%
- Food & beverage$7,8973%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 183 | $226,252 |
| Biomarin Pharmaceutical Inc. | 23 | $28,399 |
| Amicus Therapeutics, Inc. | 8 | $19,971 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $12,043 |
| Shire North American Group Inc | 4 | $7,264 |
| Chiesi USA, Inc. | 5 | $6,727 |
| Modernatx, Inc. | 3 | $1,200 |
| Amgen(2 entities) | 5 | $282 |
| AstraZeneca(2 entities) | 3 | $217 |
| Immedica Pharma US, Inc. | 1 | $128 |
| Eli Lilly | 1 | $118 |
| Eton Pharmaceuticals, Inc. | 3 | $72 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CERDELGA$58,435
- CEREZYME$33,168
- POMBILITI$19,704
- OPFOLDA$19,704
- ALDURAZYME$17,333
- XENPOZYME$17,191
- VOXZOGO 1.2mg$12,918
- LUMIZYME$7,761
- VPRIV$7,425
- ELFABRIO$4,743
- OLIPUDASE ALFA$3,508
- FABRAZYME$3,327
- NEXVIAZYME$2,758
- Palynziq$466
- Kuvan$338
- RAVICTI$134
How this compares
Too few clinical genetics (m.d.) providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Chicago
- Barbara BurtonChicago$762K
- Joshua BakerChicago$221K
- Joel CharrowChicago$189K
- William DobynsChicago$2K
- Susan EchiverriChicago$2K
- Miguel BarajasChicago$1K
- Brandon ChalazanChicago$603
- Gifty BhatChicago$149
- Mindy LiChicago$49
- George HogansonChicago$30
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.